Hetero
Dr. Mallinath S Harwalkar is currently the Vice President - R&D at Hetero. Dr. Mallinath S has extensive experience in heading various divisions within research and development in the pharmaceutical industry, specializing in sterile products, ophthalmic dosage forms, and complex injectables. Dr. Mallinath S has held positions at reputable companies such as Sentiss Pharma Pvt. Ltd., AUROBINDO PHARMA LTD, Glenmark Pharmaceuticals, and Emcure Pharmaceuticals Limited. Dr. Harwalkar holds a Master's degree in Pharmaceutics and a Bachelor's degree in Pharmacy.
This person is not in any offices
Hetero
4 followers
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc. Hetero has a strong global presence in over 145+ countries and focusses on making affordable medicines accessible to patients worldwide.